FTC is also investigating them [Barr] and their sweetheart deals with Zeneca and Bayer. Andrx/HMR deal is under investigation as well. I think its all under one roof but I may be wrong on that.
Andrx/HMR is what started it, and clearly a transaction distinct from, and with anti-competitive implications decidedly more troubling than, the ICE version of Prozac/Lilly deal.
I tend to agree with rkrw if for no other reasons than (i) another psychological/perception blow to the SEPR story and, beyond that, (ii) if SEPR can't do ICE deals with the developer of the racemic pharmaceutical, you lose time to market/structuring of trials/legacy knowledge of the side-effect and efficacy profiles, and presumably lots more.
I still subscribe to my theory that DS should never have given "official" credence to Lynn's projections (or, more precisely, the assumptions on which they were based): not only was the stock way ahead of itself at that time (didn't prevent me from adding near that point : ouch), but once the stock began re-tracing AND SEPR began pushing back NDA filings and proposed product introductions, you had not only credibility issues with the analyst but with the company as well, and with its CFO, normally the "tightwad" of any company's future financial/product performance. The 17 or 13 or whatever point run that day, to me, aggravated the subsequent drop.
Regards. Steven |
